The Brain Tumor Funders' Collaborative (BTFC) announced a request for proposals for two-year, $500,000 research grants for multi-institutional, multi-disciplinary research projects focusing on liquid ...
Biofidelity, a leader in innovative genomic solutions, today announced the launch of Aspyre Lung Reagents (research use only) for liquid biopsy samples. Aspyre Lung identifies established non-small ...
Innovative urinary miRNA profiling shows potential for early pancreatic cancer detection, with high accuracy and sensitivity, ...
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three ...
These findings will be presented at the American Association for Cancer Research Special Conference in Cancer Research: Liquid Biopsy from November 13-16, 2024, in San Diego, Calif. A new study ...
Matthias Löhr and colleagues provide an in-depth review of diagnostic methods for pancreatic incidentaloma—incidental ...
A breakthrough AI-powered liquid biopsy combining cell-free DNA and protein biomarkers improves early detection of ovarian ...
Two posters highlight the importance of epitope-independent CTC enrichment and molecular characterisation of CTCs ...
The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.
Mursla Bio in Cambridge UK and Boston in the US has been invited to join EVEREST, a leading European consortium. The ...
New study introduces a simple blood test to detect early lung damage in cancer patients receiving novel therapy with antibody–drug conjugates (ADCs), which can sometimes cause serious, even fatal, ...
As part of the deal, providers will have access to Tempus' tests such as the xT solid tumor and normal match DNA sequencing test, xR whole-transcriptome sequencing RNA test, liquid biopsy-based xF/xF+ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback